EKF Diagnostics – argues remains positive of capacity expansion “significant benefit”... but not sufficiently for the CEO to remain in situ?!EKF Diagnostics (EKF) has issued a “trading update” – it stating “reflecting strong growth in the core established business… also gives a progress update on the expansion of the Life Sciences enzyme fermentation business and on the transition of Contract Manufacturing & Laboratory Testing into non-COVID revenues”. So what of a share price response to currently 32.6p, approaching 17% lower?
- By Steve Moore
- 2023-02-06 15:30:36